

# Respiratory Research Review™

Making Education Easy

Issue 134 – 2017

## In this issue:

- *Thromboprophylaxis after knee arthroscopy and lower leg casting*
- *Predicting bleeding after VTE, with stable anticoagulation*
- *Model for predicting post partum VTE*
- *Treatment according to Hestia ±NT-proBNP testing in acute PE*
- *PERT for delivery of care for submassive/massive PE*
- *Selective TGF-β ligand trap attenuates PH*
- *BMPR2 mutation influences bronchial vascular changes in PAH*
- *Exercise pulmonary haemodynamics predict systemic sclerosis outcomes*
- *Efficacy and safety of PAH-specific therapies*
- *Upfront ambrisentan/tadalafil, together vs. alone, and mortality in PAH*

### Abbreviations used in this issue

**BMPR-2** = bone morphogenic protein type 2 receptor  
**LMWH** = low-molecular-weight heparin  
**NT-proBNP** = NT terminal of probrain natriuretic peptide  
**OR** = odds ratio  
**P(A)H** = pulmonary (arterial) hypertension  
**PE** = pulmonary embolism  
**PERT** = Pulmonary Embolism Response Team  
**RCT** = randomised controlled trial  
**TGF** = transforming growth factor  
**VTE** = venous thromboembolism

## Welcome to this issue of Respiratory Research Review on the topics of VTE (venous thromboembolism) and PAH (pulmonary arterial hypertension).

After a multitude of papers reporting on compliance with thromboprophylaxis and lack thereof, we are starting off with the N Engl J Med [article](#) by colleagues from Leiden in the Netherlands who report a lack of effect following knee arthroscopy. We go on to review great research on a prediction score to identify patients with VTE who are at risk of bleeding on anticoagulation therapy and review a risk score to predict *post partum* VTE. Finally, we reflect on a European approach to using NT-proBNP level measurements to stratify patients for outpatient treatment and a North American approach of a multidisciplinary PERT (Pulmonary Embolism Response Team) in cases of suspected PE (pulmonary embolism). The interested reader will also enjoy the French [cross-sectional evaluation](#) on the pathophysiology of dyspnoea in acute PE; a function of vascular consequences and sensory-affective domains associated with age, depression and breathing variability. Personally, and probably because I also trained during the 1980s, I most enjoyed the [editorial](#) by Donald Yealy from Pittsburgh on managing and embracing one's fears after diagnosing a PE.

Our understanding of PAH is improving, which will eventually lead to treatments beyond our current vasodilator therapies. Clinically, one of the greatest challenges is to identify the few patients with idiopathic PAH among the many patients with raised pulmonary arterial pressure secondary to heart disease and respiratory disease. Margaret Redfield from the Mayo Clinic published a [case-based clinical review](#) on 'Heart Failure with Preserved Ejection Fraction', which occurs in about 50% of patients with heart failure. Others have previously [reviewed](#) PH secondary to respiratory disease, another illness with a significant disease burden, which is difficult to manage. We highlight some primary research on the effect of selective TGF (transforming growth factor)-β ligands to attenuate PAH, the role of *BMPR2* mutations on vascular changes in PAH and the ability of exercise to predict outcomes in patients with systemic sclerosis. We end this review with two articles reflecting on the status quo of our current therapy – a meta-analysis of the efficacy and safety of single and combined PAH-specific therapy and a *post hoc* analysis of the AMBITION data, suggesting that upfront combination therapy with endothelium antagonists and phosphodiesterase inhibitors may provide a survival benefit compared with subsequential therapy.

We hope you enjoy the selection and are looking forward to feedback and comments.

Kind regards

Professor Lutz Beckert

[lutzbeckert@researchreview.co.nz](mailto:lutzbeckert@researchreview.co.nz)

KINDLY  
SUPPORTED BY



New Zealand Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).

**BREO<sup>®</sup> ELLIPTA<sup>®</sup>**  
fluticasone furoate/vilanterol

Just one inhalation,  
once daily<sup>1</sup>

Once-daily  
ICS/LABA  
Asthma  
treatment  
is here:  
Breo Ellipta<sup>1</sup>

[health.gsk.nz](http://health.gsk.nz)

*Breo<sup>®</sup> Ellipta<sup>®</sup>* (fluticasone furoate 100mcg/vilanterol trifenatate 25mcg) is a prescription medicine for the regular treatment of asthma in adults and adolescents aged 12 years and older and for the regular treatment of COPD. Before prescribing please read the Data Sheet available from [medsafe.govt.nz](http://medsafe.govt.nz) for contraindications, precautions and adverse events information. *Breo Ellipta* is not recommended for relief of acute symptoms or an acute exacerbation. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. *Breo Ellipta* was developed in collaboration with Innoviva Inc. GlaxoSmithKline NZ Limited, Auckland. 1. Breo Ellipta Data Sheet, GSK New Zealand. 2. Pharmaceutical Schedule April 2016, PHARMAC. ICS = Inhaled corticosteroid, LABA = Long-acting beta<sub>2</sub>-agonist. TAPS DA1728IG/17MA/FFT/0024/17



INNOVIVA

For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

[www.researchreview.co.nz](http://www.researchreview.co.nz)

a RESEARCH REVIEW™ publication

## Thromboprophylaxis after knee arthroscopy and lower-leg casting

**Authors:** van Adrichem RA et al., for the POT-KAST and POT-CAST Group

**Summary:** The POT-KAST (evaluable n=1451) and POT-CAST (evaluable n=1435) were parallel open-label trials that randomised patients undergoing knee arthroscopy (POT-KAST) or who required casting of the lower leg (POT-CAST) to receive or not receive anticoagulation prophylaxis with LMWH (low-molecular-weight heparin) for 8 days after knee arthroscopy or during the full period of immobilisation due to casting. There was no significant difference between the LMWH and control arms for the 3-month VTE rate in the respective POT-KAST and POT-CAST trials (0.7% vs. 0.4%; relative risk 1.6 [95% CI 0.4, 6.8] and 1.4% vs. 1.8%; 0.8 [0.3, 1.7]). Bleeding events had occurred in 0.1% of each group in POT-KAST and in none of the POT-CAST participants at 3 months. The most common adverse event was infection in both trials.

**Comment:** Several departments in Leiden, The Netherlands, including orthopaedics and thrombosis and haemostasis, with support from clinical epidemiology, medical statistics and bioinformatics collaborated to perform two parallel, pragmatic, multicentre RCTs to evaluate the efficacy of LMWH in patients following knee arthroscopy to prevent VTE. As Stephen Moll in the accompanying [editorial](#) reminds us, the evidence for VTE prophylaxis following knee arthroscopy is low and the 2012 American College of Chest Physicians didn't recommend prophylaxis in patients who don't have a history of previous VTE.

**Bottom line:** LMWH is not effective in preventing symptomatic VTE after knee arthroscopy.

**Reference:** *N Engl J Med* 2017;376(6):515–25

[Abstract](#)

## Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment

**Authors:** Klok FA et al.

**Summary:** These researchers used pooled *post hoc* analysis data from the RE-COVER studies, which compared dabigatran and standard treatment in 5107 patients with VTE, to derive a score for predicting bleeding during stable dabigatran. The resultant VTE-BLEED model included six variables and had a C statistic of 0.72 (95% CI 0.67, 0.76). In the derivation cohort, the low-risk group had a bleeding incidence of 2.8% while those in the high-risk group had an incidence of 12.6% (OR 5.0 [95% CI 3.5, 7.1]). The score was found to accurately predict the primary endpoint of major bleeding after day 30 in patients receiving dabigatran and also in those receiving warfarin (respective C statistics 0.75 [95% CI 0.61, 0.89] and 0.78 [0.68, 0.86]).

**Comment:** Offering any treatment is always a weighing up of the potential beneficial effects versus the natural history versus unwanted effects of treatment. One of the most concerning adverse effects of anticoagulation is bleeding. Here a group of European researchers used data from the dabigatran efficacy studies to identify patients at risk of bleeding. The group presents a new risk score based on six objective clinical variables: active cancer, male with uncontrolled hypertension, anaemia, history of bleeding, renal dysfunction and age older than 60 years. **Bottom line:** this VTE-BLEED score identifies the quarter of patients who have a 6-fold higher bleeding risk.

**Reference:** *Eur Respir J* 2016;48(5):1369–76

[Abstract](#)

## Development and validation of risk prediction model for venous thromboembolism in postpartum women

**Authors:** Sultan AA et al.

**Summary:** These researchers used data from England and Sweden for pregnant women with *post partum* follow-up to develop and validate a model for predicting VTE risk during the first 6 weeks after delivery. There were 433,353 and 662,387 deliveries in the respective English and Swedish cohorts, for which VTE occurred at absolute rates of 7.2 and 7.9 per 10,000 deliveries, respectively. The strongest predictors of VTE in the final multivariable model were emergency caesarean delivery, stillbirth, varicose veins, pre-eclampsia/eclampsia, *post partum* infection and comorbidities. The model had C statistic values of >0.70 in both cohorts, and calibration of observed and predicted risks was excellent. More VTE events were identified using this model than predicted by the existing English (sensitivity 68% vs. 63%) and Swedish (30% vs. 21%) guidelines at similar thresholds.

**Comment:** Considering the prothrombotic side effects of oral contraceptives is important; however, pregnancy also increases the risk of thrombosis. In the UK, VTE is one of the leading causes of maternal death and 50% of the VTE-related maternal deaths occur in the *post partum* period. In a collaboration between the UK and Sweden, the researchers use data from more than 1 million deliveries to derive and validate a new prediction model based on clinical variables available at the point of childbirth. **Bottom line:** the authors present a freely available risk prediction calculator that can be integrated into a designated website or a general practice/hospital computer system.

**Reference:** *BMJ* 2016;355:i6253

[Abstract](#)



# Upgrade your COPD patients to

# SPIOLTO®

tiotropium + olodaterol

RESPIMAT®

BUILT ON THE FOUNDATION OF  
SPIRIVA®  
(tiotropium)



www.turnopenpress.co.nz

PRESCRIPTION MEDICINE: SPIOLTO® RESPIMAT® (2.5 µg tiotropium/2.5 µg olodaterol) is indicated for the long term, once-daily maintenance treatment in patients with COPD (including chronic bronchitis and emphysema), to reduce airflow obstruction, to improve quality of life and to reduce associated dyspnoea. Before prescribing SPIOLTO RESPIMAT please review the data sheet for information on dosage, contraindications, precautions, interactions and adverse effects on the Medsafe website [www.medsafe.govt.nz](http://www.medsafe.govt.nz). Boehringer Ingelheim (N.Z.) Ltd., Auckland, Ph: 0800 802 461. 17 February 2016.

TAPS NZ/SPO-161433 PP8937




For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

## Efficacy and safety of outpatient treatment based on the Hestia clinical decision rule with or without N-terminal pro-brain natriuretic peptide testing in patients with acute pulmonary embolism

**Authors:** den Exter PL et al., for the Vesta Study Investigators

**Summary:** Outpatients with PE and none of the Hestia criteria were either discharged directly (n=275) or subjected to additional NT-proBNP level testing (n=275) in this noninferiority RCT. In the additional NT-proBNP level testing arm, 12% had an NT-proBNP level >500 ng/L and were admitted, and the remainder had lower levels and were discharged. None of the admitted patients with an elevated NT-proBNP level and none of those with a *post hoc*-determined elevated NT-proBNP level from the direct discharge group experienced a primary endpoint event (30-day PE- or bleeding-related mortality, cardiopulmonary resuscitation or intensive care unit admission). There was also no significant difference between the entire direct discharge group versus the entire additional NT-proBNP testing group for the primary endpoint event rate (1.1% vs. 0% [p=0.25]) or for the 3-month VTE recurrence rate (1.1% vs. 0.73% [p=0.65]).

**Comment:** PE is a common and potentially fatal disease, and treatment is often initialised in hospital. Evidence for treating PE as an outpatient isn't that solid, but even so, two risk prediction scores are validated: the PESI (Pulmonary Embolism Severity Index) and the Hestia clinical decision rule. In this prospective study in 17 Dutch hospitals, the authors used NT-proBNP level in addition to clinical criteria to identify patients who could be treated at home. Donald Yealy from Pittsburgh wrote a most reflective [editorial](#) on embracing and managing our fears after diagnosing PE. **Bottom line: use of clinical criteria alone was sufficient to identify patients at low risk.**

**Reference:** *Am J Respir Crit Care Med* 2016;194(8):998-1006

[Abstract](#)

## A multidisciplinary pulmonary embolism response team: initial 30-month experience with a novel approach to delivery of care to patients with submassive and massive pulmonary embolism

**Authors:** Kabrhel C et al.

**Summary:** This research prospectively evaluated the performance of a rapid-response PERT (Pulmonary Embolism Response Team) that included specialists in cardiovascular medicine/surgery, emergency medicine, haematology, pulmonary/critical care and radiology. There were 394 distinct PERT activations over a 30-month period, 80% of which were for confirmed PE, and 46% and 26% of which were for submassive and massive confirmed PEs, respectively. Every 6 months, PERT activations increased by 16%. Systemic or catheter-directed thrombolysis was used for 11% of PE cases managed by the PERT, and 69% were treated with anticoagulation alone. Haemorrhagic complications were rare, particularly among patients treated with catheter-directed thrombolysis. The 30-day all-cause mortality rate among patients with confirmed PE was 12%.

**Comment:** This is the report from the Massachusetts General Hospital PERT. PE occurs in about 1–2 per 1000 adults per year, is frequently fatal, and our treatment paradigm hasn't changed over the last 50 years despite new technology and treatments becoming available. This report summarised the patients seen, team activation, patient characteristics, PE severity, treatment offered and short- as well as long-term outcomes. The interested reader will find the [website](#) of the national PERT consortium, encompassing representatives from more than 35 centres, inspiring. **Bottom line: PERT may become the new standard of care for patients with PE.**

**Reference:** *Chest* 2016;150(2):384–93

[Abstract](#)

## RACP MyCPD Program participants

can claim **one credit per hour** (maximum of 50 credits per year) for reading and evaluating Research Reviews.

**FOR MORE INFORMATION [CLICK HERE](#)**



**• VTE Prophylaxis in:**

- General medical patients bedridden due to acute illnesses.
- Patients undergoing orthopaedic, general, major colorectal or cancer surgery.<sup>1</sup>

**• VTE treatment.<sup>1</sup>**

- UA/Non-Q-wave myocardial infarction and STEMI treatment.<sup>1</sup>
- Prevention of thrombus formation during haemodialysis.<sup>1</sup>

Please review full data sheet before prescribing (see [www.medsafe.govt.nz](http://www.medsafe.govt.nz) or available from Sanofi New Zealand, 56 Cawley Street, Ellerslie, Auckland. Freephone 0800 283 684). Clexane® is fully reimbursed for patients that meet special criteria outlined in section B of the Pharmaceutical Schedule (SA1174). For all other patients Clexane® is an unfunded Prescription medicine and Pharmacy charges and Doctors fees apply. Date of Preparation February 2016 SAANZ.ENO.16.02.0031. TAPS PP4791.



References.

1. Clexane® and Clexane® Forte Approved Data Sheet September 2015

VTE Venous Thromboembolism, which is a combination of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)  
 UA Unstable Angina  
 STEMI ST Elevation Myocardial Infarction



For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

## A selective transforming growth factor-β ligand trap attenuates pulmonary hypertension

**Authors:** Yung L-M et al.

**Summary:** Using signalling studies of cultured human pulmonary artery smooth muscle cells, these researchers investigated the impact of soluble TGFBR2-Fc (TGF-β type 2 receptor extracellular domain expressed as an immunoglobulin-Fc fusion protein), as a selective TGF-β1/3 ligand trap, in experimental models of PH in monocrotaline-treated Sprague-Dawley rats, SU5416/hypoxia-treated Sprague-Dawley rats and SU5416/hypoxia-treated C57BL/6 mice; TGFBR2-Fc inhibits TGF-β1 and TGF-β3, but not TGF-β2, signalling. *In vivo* TGFBR2-Fc treatment resulted in attenuation of Smad2 phosphorylation and normalisation of plasminogen activator inhibitor-1 expression, and also mitigated PH and pulmonary vascular remodelling in the three murine models. Right ventricular systolic pressures, right ventricular function and survival were also improved in monocrotaline-treated and SU5416/hypoxia-treated rats with established PH. No evidence of cardiac structural or valvular abnormalities emerged on treatment with TGFBR2-Fc.

**Comment:** BMPR-2 (bone morphogenic protein type 2 receptor) is a member of the TGF-β family. Enhanced signalling leads to smooth muscle hypertrophy, perivascular fibrosis, extracellular remodelling and PAH. However, general TGF-β blockers have been associated with cardiovascular and other toxicities. This Harvard group is presenting elegantly executed studies creating selective TGF-β1 and TGF-β3 blockades, sparing the TGF-β2 ligand. These TGF-β1/3 ligands reduced pulmonary vascular remodelling and PAH in three animal models. The [editorial](#) explains the **bottom line: ligand traps are entering the clinical arena and may provide new therapeutic avenues to treat PAH.**

**Reference:** *Am J Respir Crit Care Med* 2016;194(9):1140–51

[Abstract](#)

## BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension

**Authors:** Ghigna M-R et al.

**Summary:** A systematic analysis and morphometry were performed on clinical and lung histology data obtained from 44 patients with PAH to ascertain the histological profile of *BMPR2* mutation carriers. The lungs of patients with PAH who carried *BMPR2* mutations exhibited increased bronchial artery hypertrophy/dilatation, bronchial angiogenesis and muscular remodelling of septal veins. Patients with increased bronchial artery remodelling and bronchial microvessel density were more likely to experience severe haemoptysis, regardless of mutation status, but those carrying a *BMPR2* mutation more often had a history of haemoptysis >50mL. Compared with noncarriers, a greater proportion of *BMPR2* mutation carriers had singular large fibrovascular lesions (43.5% vs. 9.5%), which appeared to be closely related to the systemic lung vasculature.

**Comment:** About 70% of patients with idiopathic and 10–40% of patients with sporadic PAH have mutations in the *BMPR2* gene. This French group is exploring whether they can correlate anatomical differences to *BMPR2* receptor status in 44 of their patients who have had a lung transplant. Using a number of elegant anatomical techniques, the researchers describe the phenotype. *BMPR2* mutation carriers are more prone to haemoptysis, which in itself is related to bronchial arterial remodelling, angiogenesis and increased pulmonary venous remodelling. **Bottom line: patients with PAH and *BMPR2* mutation display a distinct clinical profile.**

**Reference:** *Eur Respir J* 2016;48(6):1668–81

[Abstract](#)

[CLICK HERE](#)

to read previous issues of Respiratory Research Review

**Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time.

**Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.

Research Review publications are intended for New Zealand health professionals.

### Independent commentary by Professor Lutz Beckert.

Professor Lutz Beckert is the Head of Department of Medicine of the University of Otago, Christchurch. He is also a Respiratory Physician at Canterbury District Health Board with particular clinical interests in interstitial lung disease, pulmonary vascular disease, respiratory physiology and COPD (chronic obstructive pulmonary disease). Lutz is happy to be contacted to discuss research ideas either as a sounding board or considering future collaborations.



## A range of products you can count on

Complete Asthma and COPD Management

8 Fully Funded Inhalers    1 Clever Dose Counter    15 Respiratory Products Across Our Range

- First fully funded dose counters on pMDIs for Fluticasone Inhalers & Salmeterol Inhaler in New Zealand
- REX Medical – a 100% New Zealand owned company committed to asthma & COPD therapy

REX Medical Asthma and COPD Inhalers, PRESCRIPTION MEDICINE. Before prescribing REX Medical Asthma and COPD Inhalers, please review the datasheet for information on dosage, contraindications, precautions, interactions, and adverse effects. Product datasheets are available at [www.medsafe.govt.nz](http://www.medsafe.govt.nz). Distributed by REX Medical Ltd, Auckland, New Zealand. TAPS NA 11747.



For more information visit [rexmedical.co.nz](http://rexmedical.co.nz)



For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

## Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis

**Authors:** Stamm A et al.

**Summary:** The prognostic value of exercise haemodynamics measured during right heart catheterisation was evaluated in patients with systemic sclerosis who had been referred for evaluation of PH. The participants were tested at rest and during maximal supine incremental cycle exercise, and grouped into the following three groups: i) resting precapillary PH (mean pulmonary artery pressure  $\geq 25$ mm Hg and pulmonary artery wedge pressure  $< 15$ mm Hg; n=17); ii) exercise-induced PH (mean pulmonary artery pressure  $\geq 30$ mm Hg and mean pulmonary artery pressure/cardiac output  $> 3$ mm Hg/L/min at maximal exercise; n=28); and iii) no PH (n=27). Median follow-up was 33 months. Compared with the group without PH, the resting precapillary PH and exercise-induced PH groups had significantly shorter estimated respective mean transplant-free survival durations (4.4 and 5.2, respectively, vs. 9.5 years [ $p < 0.05$ ]). A Cox regression analysis revealed that predictors of transplant-free survival were exercise-induced increase in mean pulmonary artery pressure (hazard ratio 1.097 [95% CI 1.002, 1.200]) and the coefficient of pulmonary vascular distensibility alpha (0.100 [0.012, 0.871]), but not resting haemodynamics.

**Comment:** Exercise-induced PAH has been abandoned as a diagnostic criterion due to insufficient data and a lack of agreement in the literature. Still it is likely that exercise-induced PAH is a precursor to progressive PAH and it may assist in identifying and treating patients early. This group from Zurich provides a significant contribution to the literature by providing data on more than 70 patients with scleroderma with median follow-up of almost 3 years. **Bottom line: exercise-induced PAH is associated with a reduced survival similar to that of patients with resting PAH.**

**Reference:** *Eur Respir J* 2016;48(6):1658–67

[Abstract](#)

## Efficacy and safety of pulmonary arterial hypertension-specific therapy in pulmonary arterial hypertension

**Authors:** Liu H-L et al.

**Summary:** This was a meta-analysis of 35 RCTs (n=6702) evaluating any PAH-specific monotherapy versus placebo/conventional therapy. Compared with placebo/conventional therapy, monotherapy was associated with significant effects on mortality (OR 0.50 [95% CI 0.33, 0.76]), New York Heart Association/WHO functional class (2.48 [1.51, 4.07]), 6-minute walk test distance (mean difference 31.10m [ $p < 0.00001$ ]), and haemodynamic status based on mean pulmonary artery pressure, pulmonary vascular resistance, cardiac index and withdrawals due to adverse effects. Compared with combination therapy, monotherapy was associated with significant effects on 6-minute walk test distance (mean difference 19.96m [ $p < 0.00001$ ]), functional class (OR 1.65 [95% CI 1.20, 2.28]), haemodynamic status and withdrawals due to adverse effects (2.01 [1.54, 2.61]), but not mortality (0.98 [0.57, 1.68]).

**Comment:** This group from China presents an astute analysis on the effect of monotherapy and combination therapy in the management of PAH. They make the observation that improvement due to adding any second agent to background PAH-specific therapy does not lead to the same magnitude of improvement as would occur if the agent had been started as monotherapy. They provide an important meta-analysis for all agents currently used. **Their bottom line: PAH-specific monotherapy improves mortality, exercise capacity, functional class and haemodynamic status; combination therapy improves it further at smaller magnitudes without an effect on mortality and with a higher incidence of adverse effects.**

**Reference:** *Chest* 2016;150(2):353–65

[Abstract](#)

- Med student
- RMO/Trainee
- GP
- Specialist
- All of the above

At all stages of your medical career, the NZMA is your voice, advocating on the issues that affect you, your colleagues and the health of all New Zealanders. A strong membership means we can do more.

**Join us today.**  
[www.nzma.org.nz](http://www.nzma.org.nz)





Support your patients with **Asthma and COPD booklets** including **Management Plans** for your practice.

[Order online here](#)


**Asthma + Respiratory**  
FOUNDATION NZ



## Idiopathic pulmonary fibrosis (IPF) treatment now funded<sup>1,2</sup>

Before prescribing Esbriet please review the data sheet for information on dosage, contraindications, precautions, interactions and adverse effects. The data sheet is available at [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

1. Esbriet® (pirfenidone) Data Sheet. Dated 26 September 2016  
2. PHARMAC 2017. Application for subsidy by special authority, SA1628. Available at <http://www.pharmac.govt.nz/2017/01/01/SA1628.pdf>. Accessed 09 January 2017.



Esbriet is a prescription only medicine, now funded for patients with IPF.<sup>1,2</sup>

Special Authority criteria apply.  
[Click here for funding criteria.](#)

PMNZ0006/TAPNSA8603/2017JAN  
Roche Products (NZ) Ltd, Auckland.

**Esbriet**  
(pirfenidone) capsules 267mg



For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

## Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension

**Authors:** Hoepfer MM et al.

**Summary:** This was a secondary analysis of the AMBITION trial, which randomised treatment-naïve patients with PAH to receive ambrisentan plus tadalafil (evaluable n=302) or each agent as monotherapy (combined n=303). This analysis focussed on mortality events from randomisation to study end, including participants who discontinued their assigned treatment. The 7-day postrandomisation mortality rate was 1% in the combination group versus 4% in both monotherapy groups combined (hazard ratio 0.21 [95% CI 0.06, 0.73]), and the respective end-of-study mortality rates were 10% and 14% (0.67 [0.42, 1.08]).

**Comment:** The AMBITION study demonstrated that upfront combination therapy with an endothelial antagonist and phosphodiesterase inhibitor showed a significant reduction in reaching the composite primary endpoint, mainly because of the reduction of hospital admissions. The primary endpoint of death only occurred in 25 (4%) of the 605 participants, although the total number of deaths was 70 (12%). This group performed a *post hoc* analysis of the AMBITION data suggesting a survival advantage of upfront combination therapy. Paul Hassoun in his [editorial](#) gives the **bottom line: upfront combination therapy may improve survival; however, this needs to be assessed by prospective studies.**

**Reference:** *Lancet Respir Med* 2016;4(11):894–901  
[Abstract](#)

Subscribe for free at  
[www.researchreview.co.nz](http://www.researchreview.co.nz)



Time spent reading this publication has been approved for CME for Royal New Zealand College of General Practitioners (RNZCGP) General Practice Educational Programme Stage 2 (GPEP2) and the Maintenance of Professional Standards (MOPS) purposes, provided that a Learning Reflection Form is completed. Please [CLICK HERE](#) to download your CPD MOPS Learning Reflection Form. One form per review read would be required.



Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs. For more information on how to claim CNE hours please [CLICK HERE](#).

### Esbriet® Abridged Prescribing Information (API)

Esbriet (pirfenidone) 267 mg oral capsule is a **Prescription Medicine** indicated for the treatment of idiopathic pulmonary fibrosis (IPF). **Dosage and Administration:** Please see Esbriet Data Sheet for information. **Contraindications:** Contraindicated in patients with a hypersensitivity to pirfenidone or any of the excipients; Patients taking fluvoxamine and patients with a history of angioedema with pirfenidone. **Precautions:** **Hepatic Function:** Elevations in ALT and AST 3 x ULN have been reported. Liver function tests should be conducted prior to and during treatment. If significant elevations occur the dose of Esbriet should be adjusted, refer to dosage guidelines in Data Sheet. Caution when used in patients with mild to moderate hepatic impairment. **Photosensitivity reaction/rash:** exposure to direct sunlight should be minimised during treatment and patients instructed to wear sunblock and protective clothing. Dosage adjustment or temporary discontinuation may be required, refer to dosage guidelines in Data Sheet; **Angioedema:** patients who develop signs or symptoms of angioedema while taking Esbriet should immediately discontinue treatment. **Cigarette smoking and inducers of CYP1A2:** exposure to pirfenidone was 50% less in patients who were smokers, concomitant use of strong inducers of CYP1A2 including smoking should be avoided. **Pregnancy Cat B3:** there are no data on the use in pregnancy. **Paediatric:** safety has not been established. **Renal Impairment:** Use with caution in patients with mild, moderate or severe renal impairment. **Drug Interactions:** Esbriet is contraindicated in patients taking fluvoxamine and caution should be taken in patients taking inhibitors of CYP1A2 e.g. ciprofloxacin, amiodarone, propafenone or inducers of CYP1A2 e.g. omeprazole, rifampicin. **Adverse Effects:** (Common only; see Data Sheet for full list); Upper respiratory tract infection; urinary tract infection; weight decreased; decreased appetite; insomnia; dizziness; somnolence; dysgeusia; lethargy; hot flush; dyspnoea; cough; productive cough; gastroesophageal reflux disease; vomiting; abdominal distension; abdominal discomfort; abdominal pain; abdominal pain upper; stomach discomfort; gastritis; constipation; flatulence; ALT increased; AST increased; gamma glutamyl transferase increased; pruritus; erythema; dry skin; rash erythematous; rash macular; rash pruritic; myalgia; arthralgia; asthenia; non-cardiac chest pain; sunburn.

ESBRIET is a funded medicine for patients with IPF who meet pre-defined criteria. Prescription and doctors' fees may apply.

Before prescribing, please review the ESBRIET Data Sheet available at [www.medsafe.govt.nz](http://www.medsafe.govt.nz). API based on Data Sheet [26-09-2016]. Roche Products (New Zealand) Limited, Auckland. Ph 0800 656 464. [www.roche.co.nz](http://www.roche.co.nz) All trademarks mentioned herein are protected by law.

PMNZ0008/TAPNSA8692/2017/JAN

For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)